Davita Inc. DVA
We take great care to ensure that the data presented and summarized in this overview for DAVITA INC. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding DVA
View all-
Warren Buffett Berkshire Hathaway Inc | Omaha, Ne32.2MShares$3.91 Billion1.63% of portfolio
-
Black Rock Inc. New York, NY4.94MShares$601 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.23MShares$514 Million0.01% of portfolio
-
State Street Corp Boston, MA1.83MShares$223 Million0.01% of portfolio
-
Invesco Ltd. Atlanta, GA1.68MShares$204 Million0.04% of portfolio
-
Morgan Stanley New York, NY1.41MShares$171 Million0.01% of portfolio
-
Gates Capital Management, Inc. New York, NY1.19MShares$145 Million3.37% of portfolio
-
Dimensional Fund Advisors LP Austin, TX1.09MShares$132 Million0.03% of portfolio
-
Geode Capital Management, LLC Boston, MA1.02MShares$124 Million0.01% of portfolio
-
Lsv Asset Management Chicago, IL927KShares$113 Million0.27% of portfolio
Latest Institutional Activity in DVA
Top Purchases
Top Sells
About DVA
DaVita Inc. provides kidney dialysis services for patients suffering from chronic kidney failure. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also provides outpatient, hospital inpatient, and home-based hemodialysis services; owns clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers. In addition, the company provides disease management services to 16,000 patients in risk-based integrated care arrangements and 7,000 patients in other integrated care arrangements; vascular access services; clinical research programs; physician services; and comprehensive kidney care services. As of December 31, 2021, it provided dialysis and administrative services in the United States through a network of 2,815 outpatient dialysis centers serving approximately 203,100 patients; and operated 339 outpatient dialysis centers located in 10 countries outside of the United States serving approximately 39,900 patients. Further, the company provides acute inpatient dialysis services in approximately 850 hospitals and related laboratory services in the United States. The company was formerly known as DaVita HealthCare Partners Inc. and changed its name to DaVita Inc. in September 2016. DaVita Inc. was incorporated in 1994 and is headquartered in Denver, Colorado.
Insider Transactions at DVA
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 04
2025
|
James O Hearty Chief Compliance Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
203
-0.77%
|
$23,954
$118.25 P/Share
|
|
Dec 04
2025
|
James O Hearty Chief Compliance Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
5,412
-16.96%
|
$638,616
$118.25 P/Share
|
|
Dec 04
2025
|
James O Hearty Chief Compliance Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,875
+15.55%
|
$634,500
$108.93 P/Share
|
|
Nov 15
2025
|
Pamela M Arway Director |
BUY
Grant, award, or other acquisition
|
Direct |
411
+1.54%
|
-
|
|
Nov 15
2025
|
Barbara J Desoer Director |
BUY
Grant, award, or other acquisition
|
Direct |
411
+50.0%
|
-
|
|
Nov 15
2025
|
Jason M. Hollar Director |
BUY
Grant, award, or other acquisition
|
Direct |
411
+6.39%
|
-
|
|
Nov 15
2025
|
Gregory J. Moore Director |
BUY
Grant, award, or other acquisition
|
Direct |
411
+5.38%
|
-
|
|
Nov 15
2025
|
Dennis W Pullin Director |
BUY
Grant, award, or other acquisition
|
Direct |
411
+16.44%
|
-
|
|
Nov 15
2025
|
Adam H Schechter Director |
BUY
Grant, award, or other acquisition
|
Direct |
411
+7.44%
|
-
|
|
Nov 15
2025
|
Wendy Lee Schoppert Director |
BUY
Grant, award, or other acquisition
|
Direct |
411
+50.0%
|
-
|
|
Nov 15
2025
|
Phyllis R Yale Director |
BUY
Grant, award, or other acquisition
|
Direct |
411
+2.86%
|
-
|
|
Nov 15
2025
|
Javier Rodriguez Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
5,165
-0.58%
|
$624,965
$121.55 P/Share
|
|
Oct 27
2025
|
Berkshire Hathaway Inc |
SELL
Open market or private sale
|
Indirect |
401,514
-1.25%
|
$54,204,390
$135.36 P/Share
|
|
Sep 22
2025
|
David Paul Maughan Chief Operating Officer, DKC |
SELL
Payment of exercise price or tax liability
|
Direct |
7,501
-5.78%
|
$975,130
$130.16 P/Share
|
|
Aug 15
2025
|
Adam H Schechter Director |
BUY
Grant, award, or other acquisition
|
Direct |
369
+7.28%
|
-
|
|
Aug 15
2025
|
Pamela M Arway Director |
BUY
Grant, award, or other acquisition
|
Direct |
369
+1.4%
|
-
|
|
Aug 15
2025
|
Gregory J. Moore Director |
BUY
Grant, award, or other acquisition
|
Direct |
369
+5.13%
|
-
|
|
Aug 15
2025
|
Jason M. Hollar Director |
BUY
Grant, award, or other acquisition
|
Direct |
369
+6.17%
|
-
|
|
Aug 15
2025
|
Barbara J Desoer Director |
BUY
Grant, award, or other acquisition
|
Direct |
369
+50.0%
|
-
|
|
Aug 15
2025
|
Phyllis R Yale Director |
BUY
Grant, award, or other acquisition
|
Direct |
369
+2.65%
|
-
|
Last 12 Months Summary
| Grant, award, or other acquisition | 80.2K shares |
|---|---|
| Exercise of conversion of derivative security | 10.5K shares |
| Open market or private sale | 4.34M shares |
|---|---|
| Payment of exercise price or tax liability | 39K shares |
| Sale (or disposition) back to the issuer | 7.78K shares |